{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Time to progression based on the myeloma response determination criteria developed by Bladé et al 1998 and is defined as the time from registration to the first documented progression. The progressive disease criteria included increasing monoclonal paraprotein levels, bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia.","groups":[{"description":"Lenalidomide 25mg by mouth (PO) daily on Days 1 to 21 in each 28 day cycle","id":"OG000","title":"Lenalidomide 25mg"}],"populationDescription":"Time to progression not analyzed per the sponsors decision.","reportingStatus":"POSTED","timeFrame":"Up to 70 months","title":"Time to Progression","type":"SECONDARY"}